2m 2m 2m 2m 2m 2m 2m
PRELUDE THERAP (PRLD)
NASDAQ
$3.63+$0.02 (+0.69%)
Price as of Oct 23, 2026 4:11 PM EDT- $234.3MMarket Cap
- 140.00%1-Year Change
- BiotechnologyIndustry
PRELUDE THERAP (PRLD)
$3.63+$0.02 (+0.69%)
PRLD | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $3.60 | ||
Change | -$0.05 (-1.37%) | ||
Open | $3.61 | ||
High | $3.73 | ||
Low | $3.47 | ||
Previous Close | $3.65 | ||
Volume | 323,757 | ||
30-Day Average Volume | 541,641 | ||
1-Week Change | 8.43% | ||
1-Month Change | -25.77% | ||
1-Year Change | 140.00% | ||
3-Year Change | 50.63% | ||
5-Year Change | -79.45% | ||
Fundamentals | |||
Shares Outstanding | 65.1M | ||
Total Assets | $189.4M | ||
Market Cap | $234.3M | ||
Enterprise Value | $207.9M | ||
Period: QTR TTM FY | |||
Revenue | $5.7M | ||
Net Income | -$13.9M | ||
Free Cash Flow | -$15.6M | ||
EBIT | -$13.9M | ||
EBITDA | -$13.6M | ||
Net Working Capital | $116.9M | ||
EPS | -$0.14 | ||
Enterprise Value/EBITDA | -15 | ||
Enterprise Value/Revenue | 36 | ||
P/B | 2 | ||
P/E | -26 | ||
PEG | 3 | ||
Price/Free Cash Flow | -15 | ||
Price/Operating Cash Flow | -15 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue